

## MANAGEMENT TEAM

Christopher J. Moreau  
Chief Executive Officer

Dr. Christopher Bryan, PhD  
Vice President Research & Operations

James Kinley, CPA, CA  
Chief Financial Officer & Director

Dr. Ahmed Khalil, PhD  
Medical Director

## BUSINESS ADVISORY BOARD

W. Bruce Rowlands

## MEDICAL & SCIENTIFIC ADVISORY BOARD

Dr. Mark Swaim, MD, PhD

Dr. Jacky Smith, MB, ChB, FRCP, PhD

Dr. Martin Kolb, MD

## BOARD OF DIRECTORS

Harry J. F. Bloomfield, QC.

Christopher J. Moreau, CEO

Raj Attariwala, MD, PhD

Dr. Mark Williams, PhD.

U.S. Ambassador (Rtd)  
Howard Gutman

## STOCK INFORMATION

(October 25, 2022)

Shares O/S: 2.357 Million  
Market Cap: C\$ 6.89 Million  
Recent Price: C\$ 2.89

## TRADING SYMBOLS

CSE: AGN

OTCQB: AGNPF

XFRA: AGWO

## INVESTOR INQUIRIES

Christopher J. Moreau, CEO

604.398.4175

chris@algernonpharmaceuticals.com

## HEAD OFFICE

Algernon Pharmaceuticals Inc.  
Suite 400 - 601 West Broadway  
Vancouver, BC, Canada, V5Z 4C2

## CORPORATE PRESENTATION


## COMPANY OVERVIEW

Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for idiopathic pulmonary fibrosis ("IPF") with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke. Two of Algernon's lead drugs are based on drug repurposing and the third compound is a naturally occurring psychedelic drug.

Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe.

We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

## ALGERNON PHARMACEUTICALS CLINICAL PIPELINE\*



\* In addition to the above, the Company is considering repurposing additional drug candidates currently in the preclinical stage

\*\* The Company is seeking non-dilutive funding mechanisms in order to advance its oncology research programs.

## ALGERNON'S LEAD CLINICAL RESEARCH PROGRAMS

### IDIOPATHIC PULMONARY FIBROSIS (IPF) AND CHRONIC COUGH

Algernon recently announced positive data showing that it met the co-primary endpoint in its Phase 2a proof of concept study evaluating NP-120 ("Ifenprodil") for the potential treatment of IPF and chronic cough. In the study, 65% of patients had stable or improved forced vital capacity ("FVC") over the 12-week treatment period with statistical significance when compared to an anticipated placebo effect of 40%. FVC is the amount of air that can be forcibly exhaled from one's lungs after taking the deepest breath possible.

For the chronic cough part of the study's primary endpoint:

- The geometric mean 24-hour cough counts were reduced by 32.0% at 4 weeks and 39.5% at 12 weeks, both with significance compared to baseline
- The geometric mean awake cough counts were reduced by 30.2% at 4 weeks and 37.4% at 12 weeks with statistical significance compared to baseline

\* The global stroke treatment market is expected to reach a value of US\$ 15 Bn by the year 2027.

### STROKE

Algernon has established a clinical research program for the treatment of stroke focused on AP-188 ("N,N-Dimethyltryptamine or DMT"), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin).

Algernon has received approval to conduct a Phase 1 clinical study of an intravenous formulation of DMT for the treatment of stroke in the Netherlands. The trial will be conducted at the Centre for Human Drug Research ("CHDR") in Leiden.

\* The IPF market is expected to reach a value of US\$ 3.2 Bn by 2025.

\* The chronic cough market is expected to reach a value of US\$ 9.8 Bn by 2027.

**RECENT DEVELOPMENTS**

**OCTOBER 24, 2022**

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

**OCTOBER 14, 2022**

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

**SEPTEMBER 19, 2022**

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

**SEPTEMBER 12, 2022**

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

**SEPTEMBER 08, 2022**

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

**SEPTEMBER 1, 2022**

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

**AUGUST 23, 2022**

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

**JULY 28, 2022**

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

**CHRONIC KIDNEY DISEASE (CKD)**

Algernon’s lead compound for the treatment and management of chronic kidney disease (“CKD”) is Repirinast, an orally administered small molecule. Repirinast acts on mast cells and inhibits the release of chemical mediators by IgE-related antigen antibody interactions. Repirinast, in a unilateral ureteral obstruction mouse model of kidney fibrosis reduced fibrosis by 50% with statistical significance. Algernon has begun manufacturing a cGMP supply of the drug and is planning a phase 1 study in Q4, 2022.

\* The global CKD drug market is expected to reach value of US\$15.8 Bn by the end of 2024.

**ALGERNON CEO INTERVIEWS**

Please visit the media section on the website for a more fulsome list of interviews.



Christopher J. Moreau  
Chief Executive Officer

- **ALGERNON PHARMACEUTICALS GAINS APPROVAL FOR PHASE 1 CLINICAL STUDY OF DMT FOR TREATMENT OF STROKE**
- **ALGERNON PHARMACEUTICALS RELEASES POSITIVE DATA FROM STUDY ON IFENPRODIL FOR IPF AND CHRONIC COUGH**
- **ALGERNON PHARMACEUTICALS PROVIDES UPDATE ON CHRONIC KIDNEY DISEASE RESEARCH PROGRAM WITH NP-251**
- **BUSINESS TELEVISION - ALGERNON’S DMT/STROKE CLINICAL PROGRAM**

**ALGERNON IN THE NEWS**

- **ALPHANORTH PARTNERS FUND - FUND COMMENTARY - AUGUST 2022**
- **WILL PHARMA CO. KEEP PUSHING HIGHER AFTER FULL DATA SET RELEASED ON LUNG DISEASE STUDY?**
- **STREETWISE REPORTS - HEDGE FUND DOUBLES POSITION IN BIOTECH CO.**
- **MARKET ONE – RETHINKING DMT: ALGERNON PHARMACEUTICALS’ NOVEL APPROACH TO STROKE TREATMENT**

**ALGERNON YEAR-TO-DATE PRICE HISTORY**



**CLICK FOR A REAL TIME QUOTE**

RESEARCH CAPITAL  
CORPORATION

André Uddin, Ph.D.  
Managing Director Healthcare  
auddin@mackieresearch.com

Algernon Pharmaceuticals is covered by Research Capital Corporation. Please note that any opinions, estimates or forecasts regarding Algernon Pharmaceuticals’ performance made by this analyst, or any other, is theirs alone and do not represent the opinions, forecasts or predictions of the Company.